449 related articles for article (PubMed ID: 16605292)
1. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.
Lübbe J; Friedlander SF; Cribier B; Morren MA; García-Díez A; Gelmetti C; Hofmann H; Houwing RH; Kownacki S; Langley RG; Virtanen M; Wolff K; Wisseh S; McGeown C; Abrams B; Schneider D;
Am J Clin Dermatol; 2006; 7(2):121-31. PubMed ID: 16605292
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC
BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121
[TBL] [Abstract][Full Text] [Related]
4. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
Ring J; Abraham A; de Cuyper C; Kim K; Langeland T; Parra V; Pigatto P; Reunala T; Szczepanski R; Möhrenschlager M; Bräutigam M; Rossi AB; Meents-Kopecky E; Schneider D
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):195-203. PubMed ID: 18211413
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
6. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
Wellington K; Jarvis B
Drugs; 2002; 62(5):817-40. PubMed ID: 11929333
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids.
Kirsner RS; Heffernan MP; Antaya R
Acta Derm Venereol; 2010; 90(1):58-64. PubMed ID: 20107727
[TBL] [Abstract][Full Text] [Related]
8. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
Staab D; Pariser D; Gottlieb AB; Kaufmann R; Eichenfield LF; Langley RG; Scott G; Ebelin ME; Barilla D; Schmidli H; Burtin P
Pediatr Dermatol; 2005; 22(5):465-71. PubMed ID: 16191004
[TBL] [Abstract][Full Text] [Related]
9. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study.
Thaçi D; Steinmeyer K; Ebelin ME; Scott G; Kaufmann R
Dermatology; 2003; 207(1):37-42. PubMed ID: 12835546
[TBL] [Abstract][Full Text] [Related]
10. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
11. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
12. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T
Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309
[TBL] [Abstract][Full Text] [Related]
13. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease.
Zuberbier T; Bräutigam M
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):718-21. PubMed ID: 18312323
[TBL] [Abstract][Full Text] [Related]
14. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
15. Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort.
Simon D; Lübbe J; Wüthrich B; Wiesner A; Weber MM; Laffitte E; Anliker MD; Schöni MH; Braathen LR; Schmid-Grendelmeier P; Gilgen Bobalj N; Schneider D
Dermatology; 2006; 213(4):313-8. PubMed ID: 17135737
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on topical pimecrolimus in atopic dermatitis.
Wellington K; Jarvis B
Am J Clin Dermatol; 2002; 3(6):435-8. PubMed ID: 12113651
[TBL] [Abstract][Full Text] [Related]
17. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
18. Pimecrolimus: a review of its use in atopic dermatitis.
Wellington K; Noble S
Am J Clin Dermatol; 2004; 5(6):479-95. PubMed ID: 15663345
[TBL] [Abstract][Full Text] [Related]
19. A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis.
Emer JJ; Frankel A; Sohn A; Lebwohl M
J Drugs Dermatol; 2011 Jul; 10(7):735-43. PubMed ID: 21720655
[TBL] [Abstract][Full Text] [Related]
20. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
